Open Label Phase 1 Dose Finding Study of TRC105 in Patients With Solid Cancer

Inclusion Criteria: * The patient has given informed consent. * The patient is willing and able to abide by the protocol. * The patient has cancer and curative therapy is unavailable. * The patient is at least 18 years old. * The patient has adequate ability to perform activities of daily living. * Significant toxicities from prior therapy must have recovered. * The patient has adequate organ function as assessed by laboratory test. Exclusion Criteria: * The patient weighs more than 264 lbs. * The patient has a known allergy to gentamicin * The patient has had prior treatment with high-dose chemotherapy requiring stem cell rescue * The patient is currently on treatment on another therapeutic clinical trial or has received an investigational agent within 4 weeks prior to first dose with study drug * The patient has had prior surgery (including open biopsy), radiation therapy or systemic therapy within 4 weeks of starting the study treatment * The patient has hypertension \> 160/90 * The patient has a history of CNS cancer * The patient has an unstable medical condition including, but not limited to, cardiac disease, history of stroke, active hepatitis, or significant pericardial, pleural or peritoneal effusion * The patient received recent thrombolytic or anticoagulant therapy * The patient has lung cancer with central chest lesions * The patient has had hemorrhage or unhealed wounds within 30 days of dosing * The patient has used systemic corticosteroids within 3 months of dosing * The patient has known HIV/AIDS * The patient has a history of hypersensitivity reaction to human or mouse antibody products * The patient is pregnant or breastfeeding. * The patient has a history of peptic ulcer disease or gastritis within 6 months of dosing, unless complete resolution has been documented by esophagogastroduodenoscopy (EGD) within 30 days of dosing